After ChatGPT and Temu, what could be the biggest 2024 stock market winners?

This writer takes a look at a couple of interesting areas of the stock market that he thinks could be poised to outperform this year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

According to Google, the search terms that increased the most in England in 2023 were ‘Temu’ and ‘ChatGPT’. Searches for Chinese shopping app Temu rocketed 2,850% year on year while those for ChatGPT jumped 2,700%. This interest was reflected in the stock market.

PDD Holdings, Temu’s owner, saw its share price surge nearly 80% in 2023. Meanwhile, the market cap of Microsoft, part-owner of ChatGPT’s parent company, rose by a staggering $1trn.

What other investing themes might take off in 2024? Here are two areas I’m watching.

Next-generation medicines

First, I think mRNA-based therapeutics might attract more investor interest. These essentially teach the body how to make its own medicine. Like software, the code can be tweaked and improved. It’s revolutionary stuff.

Shares of mRNA pioneer Moderna (NASDAQ: MRNA) shot up when its Covid vaccine based on this technology started generating billions of dollars in 2021.

But the stock has struggled badly as those pandemic sales have started drying up. In fact, it’s down around 75% in 28 months.

In 2023, Moderna expects to generate sales of at least $6bn from its Covid booster shots, then $4bn in 2024.

However, by 2025, it anticipates doubling the number of Phase 3 programs and launching up to 15 products in five years across cancer, rare disease, and infectious disease. Up to four of those launches, including a flu/Covid combo, could come by next year. This should reignite growth.

Of course, this is biotechnology, so clinical disappointments are an unavoidable risk. But the firm already has the global manufacturing capacity and $12.8bn in cash and equivalents (as of September) to fund its growth.

Plus, Moderna just announced incredible results for its experimental skin cancer vaccine. In combination with Merck’s therapy Keytruda, it lowered the risk of death or relapse in patients by half after three years. It also reduced the risk of melanoma spreading by 62%.

Each vaccine is personalised to a patient’s specific tumor and approvals could come within the next two years.

To me, this appears transformational for both patients and likely Moderna. That’s why I recently added to my holding for the first time in over three years.

Potential wonder drugs

The second area I’m bullish on this year is weight-loss treatments. Specifically Novo Nordisk‘s Ozempic (for type 2 diabetes) and Wegovy, as well as versions of the same treatments from Eli Lilly (NYSE: LLY).  

According to the World Obesity Federation, more than 4bn people will be obese or overweight within the next 12 years. That’s why these could become the best-selling drugs ever.

This potential is reflected in forward price-to-earnings (P/E) ratios of 32.5 and 50 for Novo Nordisk and Eli Lilly, respectively, for FY 2024. These aren’t cheap stocks.

However, new data suggests these drugs may also cut the risk of stroke or heart attack, and may delay kidney disease progression in diabetes patients. So the market opportunity could be a lot larger than previously anticipated.

Additionally, researchers have found that patients taking Eli Lilly’s treatment regained roughly half their previous weight one year after stopping treatment.

After both stocks dropped in response to this news I swooped in to invest. My thinking is that long-term sales may prove even stronger if patients have to continue taking the drug to keep their weight down.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Eli Lilly, Moderna, and Novo Nordisk. The Motley Fool UK has recommended Microsoft and Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Growth Shares

3 wide-moat FTSE 100 stocks that offer value today

These FTSE 100 companies have some of the widest economic moats in the index. And right now, Edward Sheldon believes…

Read more »

Investing Articles

Yielding 10.6% after a 20% decline, are abrdn shares simply too cheap to ignore?

Buying a falling knife can be a risky strategy, but Andrew Mackie believes the abrdn share price decline might be…

Read more »

Investing Articles

£20,000 in savings? Here’s how I’d aim to turn that into passive income of £994 a month

A Warren Buffett investment from 1994 returns 60% each year in dividends. With enough time, could Stephen Wright achieve a…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

If I’d put £20,000 into a FTSE 100 tracker a year ago, here’s what I’d have now

The FTSE 100 is having a great year so far this year, and it seems overdue. What's the best way…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

BP share price decline is presenting a gift for value investors

As the BP share price decline accelerates following disappointing earnings, this Fool’s long-term bullish stance has not changed.

Read more »

Investing Articles

1 S&P 500 company from my ‘best stocks to buy now’ list

Zaven Boyrazian explains why this cheap-looking S&P 500 growth enterprise is on his ‘best stocks to buy now’ list for…

Read more »

Investing Articles

Down 70%, is this former FTSE 100 name set to explode like the Rolls-Royce share price?

The Rolls-Royce share price has already flown, but Roland Head wonders if this famous FTSE 250 faller could be the…

Read more »

Black father and two young daughters dancing at home
Investing Articles

2 dividend stocks I’d buy for a lifetime of passive income

The London Stock Exchange is filled with lucrative dividend stocks waiting to be discovered. Here are two long-term winners on…

Read more »